Devonian Health Group Inc. (GSD.V)

0.2000 -0.0100 (-4.76%) At close: 09:45AM EDT

Devonian Health Group Inc.

360, rue des Entrepreneurs
Montmagny
Québec, QC G5V 4T1
Canada
514 248 7509
https://groupedevonian.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 6

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Luc D. Gregoire CA, CPA	President, CEO & Director	N/A	N/A	1960
Ms. Colette Laurin C.A., CPA	Interim CFO, Corporate Secretary & Corporate Controller	181.61k	N/A	N/A
Dr. Andre P. Boulet Ph.D.	Chief Scientific Officer & Director	644.63k	N/A	1959

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada.

Corporate Governance

Devonian Health Group Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.